$18.010
-1.661 (-9.22%)收盤時
CUE 資訊
CUE 事件
Cue Biopharma Reports Positive Phase 2 Results for CUE-221
Cue Biopharma announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a related company of Ascendant Health Limited. The trial enrolled 145 participants with moderate to severe chronic spontaneous urticaria, a disease resulting in chronic hives, that remained inadequately controlled despite treatment with H1 antihistamines. Key Highlights: Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile; Clinically different efficacy profile observed relative to XOLAIR highlights potential for a fundamental mechanism-based biological difference.
Selling Stockholders Plan to Sell 1.5M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.5M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Cue Biopharma Appoints James Ahlers as CFO
Cue Biopharma announced the appointment of James Ahlers as CFO. Ahlers will report to president and CEO Shao-Lee Lin. Prior to joining Cue, Ahlers served for nearly two decades as CFO of Intarcia Therapeutics.
Cue Biopharma Appoints Dominic Borie as Chief Medical Officer
Cue Biopharma (CUE) announced the appointment of Dominic Borie as chief medical officer, and head of research and development. He reports to president and CEO Shao-Lee Lin. Most recently, he served as strategic advisor to the CEO and board of Kyverna Therapeutics (KYTX), where he previously served as president of research and development, and founding CEO.
Cue Biopharma Completes $50 Million Private Placement
Cue Biopharma announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 1.418M shares of common stock at a purchase price of $33.21 per share and to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 87,500 shares of common stock at a price per pre-funded warrant of $33.209, for gross proceeds of approximately $50M. The private placement is expected to close on or about July 13, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of $0.001 per share, be immediately exercisable, and remain exercisable until exercised in full. The private placement was led by Cormorant Asset Management, with participation from additional new investment funds including Columbia Threadneedle Investments. The company intends to use the net proceeds from the private placement to further fund clinical development and for other general corporate purposes.
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。